175 related articles for article (PubMed ID: 38667328)
1. 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer.
Shao J; Xu Y; Olsen RJ; Kasparian S; Sun K; Mathur S; Zhang J; He C; Chen SH; Bernicker EH; Li Z
Cells; 2024 Apr; 13(8):. PubMed ID: 38667328
[TBL] [Abstract][Full Text] [Related]
2. Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis.
Shao J; Olsen RJ; Kasparian S; He C; Bernicker EH; Li Z
Cells; 2024 Feb; 13(4):. PubMed ID: 38391911
[TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.
Shao J; Wang S; West-Szymanski D; Karpus J; Shah S; Ganguly S; Smith J; Zu Y; He C; Li Z
Sci Rep; 2022 Jul; 12(1):12410. PubMed ID: 35859008
[TBL] [Abstract][Full Text] [Related]
4. Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer.
Guler GD; Ning Y; Coruh C; Mognol GP; Phillips T; Nabiyouni M; Hazen K; Scott A; Volkmuth W; Levy S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38212123
[TBL] [Abstract][Full Text] [Related]
5. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers.
Zhou M; Hou P; Yan C; Chen L; Li K; Wang Y; Zhao J; Su J; Sun J
Clin Epigenetics; 2021 Oct; 13(1):197. PubMed ID: 34689838
[TBL] [Abstract][Full Text] [Related]
9. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
10. Integrated 5-hydroxymethylcytosine and fragmentation signatures as enhanced biomarkers in lung cancer.
Hu X; Luo K; Shi H; Yan X; Huang R; Zhao B; Zhang J; Xie D; Zhang W
Clin Epigenetics; 2022 Jan; 14(1):15. PubMed ID: 35073982
[TBL] [Abstract][Full Text] [Related]
11. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma.
Xiao Z; Wu W; Wu C; Li M; Sun F; Zheng L; Liu G; Li X; Yun Z; Tang J; Yu Y; Luo S; Sun W; Feng X; Cheng Q; Tao X; Wu S; Tao J
Mol Oncol; 2021 Jan; 15(1):138-150. PubMed ID: 33107199
[TBL] [Abstract][Full Text] [Related]
12. Alterations of 5-hydroxymethylcytosines in circulating cell-free DNA reflect retinopathy in type 2 diabetes.
Han L; Chen C; Lu X; Song Y; Zhang Z; Zeng C; Chiu R; Li L; Xu M; He C; Zhang W; Duan S
Genomics; 2021 Jan; 113(1 Pt 1):79-87. PubMed ID: 33221518
[TBL] [Abstract][Full Text] [Related]
13. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
14. 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer's Disease.
Chen L; Shen Q; Xu S; Yu H; Pei S; Zhang Y; He X; Wang Q; Li D
J Alzheimers Dis; 2022; 85(2):573-585. PubMed ID: 34864677
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers.
Li W; Zhang X; Lu X; You L; Song Y; Luo Z; Zhang J; Nie J; Zheng W; Xu D; Wang Y; Dong Y; Yu S; Hong J; Shi J; Hao H; Luo F; Hua L; Wang P; Qian X; Yuan F; Wei L; Cui M; Zhang T; Liao Q; Dai M; Liu Z; Chen G; Meckel K; Adhikari S; Jia G; Bissonnette MB; Zhang X; Zhao Y; Zhang W; He C; Liu J
Cell Res; 2017 Oct; 27(10):1243-1257. PubMed ID: 28925386
[TBL] [Abstract][Full Text] [Related]
16. 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.
Chen HY; Zhang WL; Zhang L; Yang P; Li F; Yang ZR; Wang J; Pang M; Hong Y; Yan C; Li W; Liu J; Xu N; Chen L; Xiao XB; Qin Y; He XH; Liu H; Zhu HC; He C; Lin J; Jing HM
Clin Epigenetics; 2021 Feb; 13(1):33. PubMed ID: 33573703
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients.
Gao P; Lin S; Cai M; Zhu Y; Song Y; Sui Y; Lin J; Liu J; Lu X; Zhong Y; Cui Y; Zhou P
J Cell Mol Med; 2019 May; 23(5):3530-3537. PubMed ID: 30912288
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma.
Chiu BC; Zhang Z; You Q; Zeng C; Stepniak E; Bracci PM; Yu K; Venkataraman G; Smith SM; He C; Zhang W
Blood Adv; 2019 Oct; 3(19):2790-2799. PubMed ID: 31570490
[TBL] [Abstract][Full Text] [Related]
19. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
20. Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer.
Cao F; Wei A; Hu X; He Y; Zhang J; Xia L; Tu K; Yuan J; Guo Z; Liu H; Xie D; Li A
Clin Epigenetics; 2020 Jul; 12(1):112. PubMed ID: 32703318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
